Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden

Ankur R Parikh,1 Siraj M Ali,2 Alexa B Schrock,2 Lee A Albacker,2 Vincent A Miller,2 Phil J Stephens,2 Pamela Crilley,1 Maurie Markman1 1Eastern Regional Medical Center, Cancer Treatment Centers of America, Philadelphia, PA, USA; 2Foundation Medicine, Inc, Cambridge, MA, USA Abstract: In non-small-c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Parikh AR, Ali SM, Schrock AB, Albacker LA, Miller VA, Stephens PJ, Crilley P, Markman M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	genomic profiling temsirolimus targeted therapy immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a9885aaa64554810b46149e8add182b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a9885aaa64554810b46149e8add182b2
record_format	dspace
spelling	oai:doaj.org-article:a9885aaa64554810b46149e8add182b22021-12-02T05:13:56ZResponse to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden1179-2728https://doaj.org/article/a9885aaa64554810b46149e8add182b22018-05-01T00:00:00Zhttps://www.dovepress.com/response-to-rapamycin-analogs-but-not-pd-1-inhibitors-in-pten-mutated--peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Ankur R Parikh,1 Siraj M Ali,2 Alexa B Schrock,2 Lee A Albacker,2 Vincent A Miller,2 Phil J Stephens,2 Pamela Crilley,1 Maurie Markman1 1Eastern Regional Medical Center, Cancer Treatment Centers of America, Philadelphia, PA, USA; 2Foundation Medicine, Inc, Cambridge, MA, USA Abstract: In non-small-cell lung cancer (NSCLC) refractory to standard therapy and which lacks well-known oncogenic drivers, genomic profiling can still identify genomic alterations that may suggest potential sensitivity to targeted therapy. PTEN mutation in NSCLC may be sensitizing to analogs of rapamycin such as everolimus or temsirolimus, but more investigation is needed. We report the case of a patient with metastatic NSCLC harboring a PTEN mutation as well as high tumor mutational burden and PD-L1 positivity with a durable response to temsirolimus, but refractory to a checkpoint inhibitor. Even in the event of failure of treatment with checkpoint inhibitors in the background of a case with a higher tumor mutational burden and PD-L1 positivity, targeting specific genomic alterations may still result in patient benefit. Keywords: genomic profiling, temsirolimus, targeted therapy, immunotherapyParikh ARAli SMSchrock ABAlbacker LAMiller VAStephens PJCrilley PMarkman MDove Medical Pressarticlegenomic profilingtemsirolimustargeted therapyimmunotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 9, Pp 45-47 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	genomic profiling temsirolimus targeted therapy immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	genomic profiling temsirolimus targeted therapy immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Parikh AR Ali SM Schrock AB Albacker LA Miller VA Stephens PJ Crilley P Markman M Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
description	Ankur R Parikh,1 Siraj M Ali,2 Alexa B Schrock,2 Lee A Albacker,2 Vincent A Miller,2 Phil J Stephens,2 Pamela Crilley,1 Maurie Markman1 1Eastern Regional Medical Center, Cancer Treatment Centers of America, Philadelphia, PA, USA; 2Foundation Medicine, Inc, Cambridge, MA, USA Abstract: In non-small-cell lung cancer (NSCLC) refractory to standard therapy and which lacks well-known oncogenic drivers, genomic profiling can still identify genomic alterations that may suggest potential sensitivity to targeted therapy. PTEN mutation in NSCLC may be sensitizing to analogs of rapamycin such as everolimus or temsirolimus, but more investigation is needed. We report the case of a patient with metastatic NSCLC harboring a PTEN mutation as well as high tumor mutational burden and PD-L1 positivity with a durable response to temsirolimus, but refractory to a checkpoint inhibitor. Even in the event of failure of treatment with checkpoint inhibitors in the background of a case with a higher tumor mutational burden and PD-L1 positivity, targeting specific genomic alterations may still result in patient benefit. Keywords: genomic profiling, temsirolimus, targeted therapy, immunotherapy
format	article
author	Parikh AR Ali SM Schrock AB Albacker LA Miller VA Stephens PJ Crilley P Markman M
author_facet	Parikh AR Ali SM Schrock AB Albacker LA Miller VA Stephens PJ Crilley P Markman M
author_sort	Parikh AR
title	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
title_short	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
title_full	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
title_fullStr	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
title_full_unstemmed	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
title_sort	response to rapamycin analogs but not pd-1 inhibitors in pten-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/a9885aaa64554810b46149e8add182b2
work_keys_str_mv	AT parikhar responsetorapamycinanalogsbutnotpd1inhibitorsinptenmutatedmetastaticnonsmallcelllungcancerwithhightumormutationalburden AT alism responsetorapamycinanalogsbutnotpd1inhibitorsinptenmutatedmetastaticnonsmallcelllungcancerwithhightumormutationalburden AT schrockab responsetorapamycinanalogsbutnotpd1inhibitorsinptenmutatedmetastaticnonsmallcelllungcancerwithhightumormutationalburden AT albackerla responsetorapamycinanalogsbutnotpd1inhibitorsinptenmutatedmetastaticnonsmallcelllungcancerwithhightumormutationalburden AT millerva responsetorapamycinanalogsbutnotpd1inhibitorsinptenmutatedmetastaticnonsmallcelllungcancerwithhightumormutationalburden AT stephenspj responsetorapamycinanalogsbutnotpd1inhibitorsinptenmutatedmetastaticnonsmallcelllungcancerwithhightumormutationalburden AT crilleyp responsetorapamycinanalogsbutnotpd1inhibitorsinptenmutatedmetastaticnonsmallcelllungcancerwithhightumormutationalburden AT markmanm responsetorapamycinanalogsbutnotpd1inhibitorsinptenmutatedmetastaticnonsmallcelllungcancerwithhightumormutationalburden
_version_	1718400490767646720

Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden

Ejemplares similares